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Mucus hypersecretion accompanies such pulmonary diseases as asthma, bron- 
chitis, and pneumonia. While some of the factors capable of influencing mucus 
secretion have been identified (1-9),  no investigations into the possible interac- 
tion of activated complement products with mucus secretion have been reported. 
During  the  course  of complement  activation  by  either  the  alternative or  the 
classical pathway, anaphylatoxins are generated that are capable of causing mast 
cell and basophil degranulation, inducing bronchial smooth muscle spasm and 
attracting polymorphonuclear leukocytes.  It  is  possible  that immunologic pul- 
monary inflammatory reactions are accompanied by anaphylatoxin generation, 
particularly during the course of fungal or bacterial infections (10), and perhaps 
in  association with other airway diseases as well.  Thus,  we were  interested in 
determining whether the anaphylatoxin C3a was capable of influencing mucous 
glycoprotein (MGP) 1 secretion in vitro. 
Materials and Methods 
Reagents.  We used CMRL-1066 medium, penicillin, streptomycin, and amphotericin 
B (Gibco  Laboratories, Grand Island, NY); [~H]glucosamine  (20  Ci/mM) (ICN, Irvine, 
CA);  [3H]leukotriene C4 (LTC4)  (35.7  Ci/mM) (New  England Nuclear,  Boston, MA); 
Ultrafluor (National Diagnostics  Inc., Somerville, N  J); trichloroacetic acid (J. T. Baker 
Chemical Co.,  Phillipsburg, N  J); cycloheximide (Sigma  Chemical Co., St.  Louis, MO); 
phosphotungstic acid (Mailinckrodt Inc., St. Louis, MO); and LKGD analytical thin-layer 
chromatography (TLC) precoated plates (Whatman Laboratory Products Inc., Clifton, 
N  J). All other materials were obtained as cited in a previous study (6). 
Preparation  of Human Airways for Culture.  Human lungs were obtained at surgery, 
primarily from tumor resections. Normal-appearing airways, 2-10 mm in diameter, were 
fragmented into replicates and cultured as previously described (4, 6). The airway explants 
were maintained in CMRL-1066 medium with penicillin (100 #g/ml), streptomycin (100 
ug/ml), and amphotericin B (0.5 ug/ml), in a controlled-atmosphere chamber gassed with 
45% 02, 50% N2, and 5% CO2, and incubated at 37°C. 
1  Abbreviations used in this paper:  ETYA,  eicosatetraynoic  acid; HETE, hydroxy-eicosatetraenoic 
acid; HPLC, high-pressure liquid chromatography; LTC4, leukotriene C4; MGP, mucous glycopro- 
rein; MMS, macrophage-derived mucus secretagogue; PBS, phosphate-buffered saline; TLC, thin- 
layer chromatography. 
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Radiolabeling of MGP.  MGP were radiolabeled by incorporating [3H]glucosamine (1 
/~Ci/ml)  from  the  culture  medium.  Explants  were  initially  incubated  for  16  h  in  the 
absence of [3H]glucosamine,  washed twice  with  media, and  then  incubated  with  [3H]- 
glucosamine  for  a  16-h  baseline  period  (period  I).  The  period  I  supernatants  were 
harvested; fresh culture  medium without glucosamine was added for an additional  4-h 
period  (period  II), and  the  culture  supernatants  were subsequently  harvested.  Airway 
cultures were cycled through  16-h baseline incubations (period I) and 4-h experimental 
incubations (period II) for up to 8 d. 
One-milliliter aliquots of the culture medium and washes from period I and period II 
were added to 1 ml of 10% trichloroacetic acid and 2% phosphotungstic acid. After 16 h 
at  4°C,  the  samples were centrifuged for 5  rain  at  2,500  g, and  the  supernatant  was 
decanted.  The pellet was washed twice with  10%  trichloroacetic acid and  1% phospho- 
tungstic acid, and resuspended in  1 ml of 0.2  M NaOH. The suspension was vortexed, 
incubated at 22°C for 12 h, and vortexed again; 0.5-ml aliquots were then added to 10 
ml of Ultrafluor and counted in a Beckman 8100 scintillation counter (Beckman Instru- 
ments, Inc., Cedar Grove, NJ). 
Effect of Pharmacologic Manipulations on the Release of MGP.  The effect of pharmaco- 
logic manipulations on the release of [3H]glucosamine-labeled MGP was determined by 
adding agents to cultures at the beginning of period II. The ratio of cpm of period II to 
cpm of period  I  for each sample was termed  the  secretory index.  The effects of the 
pharmacologic agents were determined by comparing the secretory indices of manipulated 
samples with matched, unmanipulated control samples. Controls were derived from the 
same tissue,  cultured  in  parallel,  and  handled  identically to the  experimental samples, 
except that the pharmacologic agents were not added. Thus, each airway culture provided 
its own baseline period (period I) as well as a stimulated period (period II), and the effects 
of each pharmacologic manipulation could be compared with matched controls. 
Complement Components and  Antibody Preparations.  C3a  was  prepared  from  highly 
purified human C3 (1 I), under conditions exactly as previously described (12).  The C3a 
was concentrated with Amicon UM-2 membranes and dialyzed against phosphate-buffered 
saline (PBS) with the use of spectra-Por 3 tubing. The protein concentrations of the C3a 
preparations were measured using a microbiuret assay (13) with bovine serum albumin as 
a standard. At pH 8.3, the C3a produced a typical cationic precipitin arc in immunoelec- 
trophoresis against a burro monospecific antiserum (14).  Intact C3 also precipitated with 
the anti-C3a antiserum, but C3b failed to react. The C3a fragment failed to react with 
sheep or goat antisera to trypsin-degraded C3b. These antisera were the kind gift of Dr. 
Carl Hammer, NIH, and have been described elsewhere (14). An anti-C3a immunoadsor- 
bent was prepared by incubating 1 ml of the anti-C3a serum for 2 h at room temperature 
with 1.5 ml of packed staphylococcal protein A-conjugated Sepharose CL-4B (Pharmacia 
Fine Chemicals, Uppsala, Sweden) in PBS-carbonate buffer at pH 8.2. The absorbent was 
washed five times with the same buffer, then 42 ~g C3a was added, and incubated for 1 
h  at room temperature. As a control, an equivalent aliquot of C3a was incubated with 
another 1.5-ml aliquot of protein A-Sepharose that had not been preincubated with the 
antiserum. Following incubation, the absorbent and control Sepharose were removed by 
centrifugation, the pH of the supernatants were adjusted to 7.3 with 2-3 ~1 of IN HCI, 
and  the  supernatants were filtered  through  0.22-/am membranes. F(ab')~ fragments of 
anti-C3a were prepared as described (15).  C3a des Arg was prepared by cleavage of the 
purified C3a with the use of 1% (wt/wt) diisopropylfluorophosphonate-treated carboxy- 
peptidase B. An anodal shift of the C3a des Arg relative to the uncleaved C3a was the 
immunoelectrophoretic indicator used to confirm cleavage. 
Characterization of LTC4.  Culture medium containing LTC4 was chromatographed by 
TLC using a one dimensional, ascending system developed in propanol/ammonia/water 
(6:3:1) (16).  [SH]LTC4 migrated with an Rf of 0.58.  Leukotrienes in tissue culture media 
from cultured human airways were also analyzed by high-pressure liquid chromatography 
(HPLC)  as  described  (17).  The  HPLC  analyses  were  kindly  performed  by  Dr. Jack 
Vanderhook of George Washington University in Washington DC. 
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by the automated fluorometric assay (18).  Anti-human IgE was prepared as previously 
described (19). 
Statistical  Analysis,  The data  were analyzed by paired  sample t  tests with P  <0.05 
considered statistically significant.  In experiments analyzing the effects of secretagogues 
on MGP release, five replicate tissue culture plates were used to generate each experi- 
mental point. All results represent data derived from experiments that were repeated on 
several different human lungs. The results are provided as the mean +SEM. 
Results 
To  determine  whether  C3a  was  capable  of causing  an  increase  in  mucous 
glycoprotein release from human airways in culture,  four separate airway prep- 
arations were exposed to purified C3a in concentrations  from 0.5  to  15 ~g/ml 
(Table I). C3a caused a dose-dependent increase in MGP release at concentrations 
above 0.5 #g/ml, all of which were significantly above control levels. 
The  ability  of C3a  des Arg  to affect  MGP release was compared  to  that  of 
native C3a (Table II). C3a des Arg failed to cause increased MGP release at 5- 
20 ug/ml, while active C3a caused a  35% increase in the same experiments. 
Effect  of Anti-C3a.  To  determine  whether  the  C3a  effect  on  the  airways 
reflected a specific interaction, the following experiments were performed (Table 
III).  Anti-C3a  F(ab')2  were  prepared  as  previously  described  (15).  Antibody 
concentrations of 5,  10, and 50 tA/plate were added to human airways in culture 
at the beginning of period II. None of these antibody preparations had any effect 
TABLE  I 
Effect of C3a on MGP Release From Human Airways in Culture 
MGP release (percent increase above  C3a  control; n -- 4) 
ug/mt 
0.5  7.3 _  1.0 
5  25.0 +  1.3 
10  30.0 +_ 3.5 
15  40.0 :t: 2.0 
TABLE II 
Effect of C3a vs. C3a des Arg on MGP Release 
MGP release (percent increase above  Treatment  control; n = 2) 
#g/ml 
C3a des Arg 
t~g/ml 
5.2  11 -  0.5 
7.8  9 + 0.5 
10.4  8 -4-_ 0.4 
20.8  3 _+ 0.2 
C3a 
#g/ml 
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TABLE  III 
Effect of C3a and Anti-C3a on MGP Release 
Airways incubated with: 
MGP release (percent in- 
crease above control) 
(n = 2 for each experi- 
ment) 
Exp. 1  * 
C3a, 20 gg/ml  33 _+ 0,5 
Anti-C3a*, 5 tA/plate  2 _+ 0.8 
Anti-C3a plus C3a  9 +  1.2 
Exp. 2  ° 
C3a, 10 ug/ml  35 _  1.2 
Anti-C3a, 10 #l/plate  l 1 _ 4.0 
Anti-C3a plus C3a  2 --+ 1.0 
Methacholine, 1 ~tM  38 _+ 2.0 
Anti-C3a plus methacholine  35 _+ 1.0 
* Airways were preincubated  with anti-C3a for 20  min, then  C3a was 
added. 
* Anti-C3a, in concentrations of 5,  10, and 50/~l/plate  had no effect on 
the release MGP. 
0 Anti-C3a and C3a were added to airways at the same time. 
on  MGP  release  when  examined  alone.  In  experiment  I,  the  airways  were 
preincubated for 20 rain with 5 gl/plate of antibody, then C3a (20 #g/plate) was 
added (Table III, experiment  1). C3a in the absence ofantisera increased mucus 
release  33%  above  the  control  level,  anti-C3a  alone  had  no  effect  on  mucus 
release, and pretreatment of the airways with the antibody significantly inhibited 
the stimulatory effect of C3a (73% inhibition).  Addition of control rabbit sera to 
C3a-treated airways had no effect on C3a-induced  MGP release. 
In a different experiment (Table III, experiment 2), anti-C3a alone again had 
no  effect  on  MGP  release,  while  C3a  alone  enhanced  mucus  release  to  35% 
above control.  When C3a was added simultaneously with anti-C3a,  it produced 
no  increase  in  MGP  release.  Methacholine  (1  ttM),  a  known  mucus-secretion- 
stimulator (!-4), enhanced mucus release to 38% above control, and the presence 
of anti-C3a did  not  affect  the  secretion-stimulating  activity  of  methacholine. 
Thus,  while C3a is capable of enhancing  mucus release from human airways in 
vitro, its activity is significantly inhibited  by anti-C3a, and this inhibitory action 
is  specific  for  C3a.  In  other  experiments  (not  shown),  anti-C3a  also  failed  to 
affect histamine or C5a-induced  MGP release. 
Specific  Immunoabsorption.  In  order  to  further  investigate  the  specificity of 
the  anti-C3a and  its capacity to inhibit  the  effect of C3a on  human  airways in 
culture,  we examined the  effects of absorbing and  washing C3a from a  Sepha- 
rose-protein A-antibody immunoabsorption mixture, or from a  control Sepha- 
rose-protein A mixture. Native C3a, anti-C3a alone, antibody plus C3a, and C3a 
exposed to a Sepharose-protein A-antibody conjugate or to control Sepharose- 
protein  A  were added  to human  airways in  culture  to determine  whether  they 
influenced  MGP release (Table IV). 20,  50, and  100 #l/plate of buffer alone, as 
well  as  5,  10,  20,  and  50  #l/plate  of antibody  alone  had  no  effect on  mucus 
release. C3a alone (Table IV, A) increased MGP release in a dose-related manner. MAROM  ET  AL.  661 
C3a was totally absorbed by the Sepharose-protein A-anti-C3a affinity conjugate 
and  did  not  elute  with  buffer  washes  (Table  IV,  B).  C3a  that  was  added  to 
Sepharose-protein  A  alone  was  not  absorbed,  as  reflected  by  its  continued 
secretion-stimulating activity (Table IV, C). Thus, it appears that the interaction 
between C3a and the anti-C3a antibody is specific. 
Mechanisms of Action: Mast Cell Degranulation.  C3a is capable of causing mast 
cell  degranulation  (20)  and  can  induce  alveolar macrophages to  become "acti- 
vated"  and  release  enzymes  (21).  Diverse  mast  cell  mediators  (4,  6-9)  and  a 
recently  recognized  macrophage  product  termed  macrophage-derived  mucus 
secretagogue (MMS) (22) are capable of causing mucus secretion.  It was, there- 
fore,  important  to  determine  whether  the  C3a  effect  on  MGP  release  acted 
directly on mucous glands, or through either mast cell degranulation  or macro- 
phage MMS release. 
Purified C3a was added  to airways in culture  in concentrations of 5,  10, and 
15/zg/ml,  and  the  supernatants  were collected and assayed for both  MGP and 
histamine. As shown in Table V, C3a stimulated mucus release in all concentra- 
tions examined, but did not cause an increase in histamine release. Samples from 
three different lung experiments were assayed for histamine release after expo- 
sure  to  C3a,  and  in  each  instance,  no  histamine  release  was  observed.  To 
determine whether the histamine that might have been released into the culture 
medium  was  metabolized  during  the  4-h  incubation,  histamine  (1,650  ng/ml) 
was incubated with airways for up to 4 h. The histamine in the medium remained 
TABLE  IV 
Specific Immunoadsorption of C3a 
MGP release (percent in- 
Airways incubated with:  crease above control 
A.  C3a: 
uglml 
2.5  15 --- 0.2 
5  24 + 0.3 
10  36 +  0.6 
B.*  C3a after exposure to Sepharose-protein 
A-anti-C3a immunoadsorption and washing 
tag/ml 
10  8+0.3 
25  6 + 0.5 
50  9 -  0.8 
C.*  C3a after exposure to Sepharose-protein  A 
and washing: 
#g/ml 
10  16 --- O.7 
25  21 --- O.2 
5O  32 -  0.3 
* Because the  concentration  of C3a  after  column  washes is  1/10  of the  starting 
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TABLE  V 
C3a Effects on MGP and Histamine Release 
C3a 
MGP release  Histamine release 
(percent increase  C3a-treated 
above control)  Control airways  airways 
tag/ml  ng/ml 
5  21  4- 0.9  6.4 4- 0.2  6.3 -+ 0.3 
10  33 4- 0.3  6.5 +  0.4  6.7 4- 0.2 
15  43 4- 0.5  6.0 +  0.2  6.2 4- 0.1 
C3a was added to airways, and the supernatants were assayed for MGP 
release or for histamine. Control airways were treated with tissue culture 
media alone. 
TABLE VI 
Comparison of C  3a and Reversed Anaphylaxis-induced Histamine 
Release and MGP Secretion From Human Airways 
Hista-  MGP release 
Experimental condition  mine  (percent increase 
release  above control) 
ng/ral 
Dibutyryl cAMP (1 mM)  8  9.5 4- 2.5 
Anti-lgE ( 1  : 100)  42  20.0 4- 1.5 
Anti-IgE plus dibutyryl cAMP  10  9.5 4- 0.5 
C3a (10 #g/ml)  5  28.0 4- 5.5 
C3a plus dibutyryl cAMP  8  24.0 4- 3 
stable throughout the incubation, indicating that metabolism cannot account for 
the observed absence of histamine  release.  Thus, C3a stimulates mucus release 
apparently without causing detectable histamine release. 
In  order  to  further  investigate  the  relationship  between C3a-induced  MGP 
release and mast cell activation, the same experiments were used to compare the 
actions of C3a to reversed anaphylaxis,  using rabbit anti-human  IgE (19). C3a 
caused MGP release but no histamine  release (Table VI), while anti-IgE caused 
both histamine and MGP release. It is well-documented that increased cAMP in 
lung tissue suppresses mast cell activation (23); therefore, the effects of dibutyryl 
cAMP on C3a and anti-IgE-induced reactions were compared, cAMP alone had 
minimal  effects on  MGP and  histamine  release,  while  reducing  the  ability of 
reversed anaphylaxis to stimulate either response. However, cAMP had no effect 
at  all  on  C3a-induced  MGP  release.  Thus,  these  data  strongly  support  the 
suggestion  that  C3a  is not acting  to stimulate  MGP release  through  mast  cell 
degranulation. 
Oxidative Products Derived From Arachidonic Acid.  To investigate whether the 
effect of C3a on mucus release might act through generating oxidative products 
derived from arachidonic  acid, airways were incubated with  the following: (a) 
5,8,11,14-eicosatetraynoic acid (ETYA) (35 •g/ml),  which, in this concentration, 
is  capable  of blocking  both  the  cyclooxygenase and  lipoxygenase pathways of 
arachidonic acid metabolism in the lung (6); (b) C3a; (c) ETYA plus C3a (added 
simultaneously); or (d) C3a plus ETYA (with the ETYA added  20 min  before MAROM ET  AL.  663 
the C3a) (Table VII).  ETYA alone decreased  MGP release (6);  C3a (5 ug/ml) 
increased mucus release; and with either experimental  design, C3a in the pres- 
ence of ETYA increased mucus release. Thus, ETYA did not significantly affect 
the ability of C3a to stimulate MGP release. These data suggest that the actions 
of C3a do not involve generation of oxidative derivatives of arachidonic acid. 
To further assess the possibility of C3a-induced ieukotriene production, pooled 
supernatants obtained from the ETYA plus C3a-treated airways, were acidified 
to  pH  3.0  and  extracted  with  diethylether,  as  previously  described  (6).  The 
organic and aqueous phases were both assayed by HPLC for leukotrienes.  No 
leukotrienes B, C, or D were detected. These experiments thus suggest that the 
activity of C3a on airways is not mediated through the generation of detectable 
amounts of leukotrienes. 
As it was possible that leukotrienes generated by C3a-stimulated airways might 
be metabolized under the experimental conditions, it was essential to determine 
whether  the  leukotrienes  in  the  culture  medium  were  stable  for  up  to  4  h. 
Therefore,  [~H]LTC4 was added to the airways in culture,  and aliquots of the 
incubation  medium  were removed  30-240  rain  later.  After acidification,  the 
medium was extracted into ethyl acetate, and chromatographed  on TLC.  Au- 
thentic LTC4 migrated with an R~ of 0.58, as did the radioactivity in each aliquot. 
The authentic  LTC4  migrated with  12,000  cpm/ml at time 0;  LTC4 migrated 
with  12,240  cpm/ml  after  30  rain  of  incubation  with  lung  tissue;  11,460 
cpm/ml  after  120  min;  and  11,790  cpm/ml  after  240  min.  Therefore,  no 
significant  metabolism  of LTC4  takes place during  human  airway incubations 
lasting up to 4 h. Moreover, these data strongly support the conclusion that C3a- 
induced  MGP release is independent  of leukotriene  (or other eicosanoid) gen- 
eration. 
MMS Generation.  Next, we investigated the possibility that C3a acts through 
the generation of MMS by pulmonary macrophages.  Initially, the time course of 
C3a-induced MGP release was determined to see whether it paralleled the time 
course for the appearance  of MMS activity from macrophages  in vitro (Table 
VIII). C3a-induced MGP release is appreciable after a  1-h incubation, and peaks 
by 6  h.  MMS release from macrophages peaks in 2-4 h  after stimulation (22). 
Thus,  it  seemed possible that  C3a  interacted  with  macrophages  in  culture  to 
stimulate MMS release which, in turn,  increased MGP release. 
MMS is synthesized by macrophages through a  cycloheximide-sensitive path- 
way (22). Therefore, we reasoned that exposure of airways to cycloheximide for 
16 h before adding C3a should suffice to determine whether C3a was acting by 
TABLE VII 
Effect of Influencing Arachidonic Acid Metabolism on C3a-induced 
MGP Release 
MGP release (percent 
Airways incubated with:  change from control) 
ETYA (35 #g/ml)  -25 _+ 1.4 
C3a (5 #g/ml)  +27 + 2.0 
ETYA plus C3a: 
Simultaneous addition  +29 _+ 0.9 
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TABLE  VIII 
Time Course of MGP Release From Human Airways Exposed to C3a 
Time of incubation after C3a  MGP release (percent increase above 
addition  control) 
h 
0.5  8.4 -e 2.0 
1  28.5 4- 0.5 
2  30.5 +  0.5 
4  39.5 ±  0.5 
6  42.0 _+ 1.0 
8  25.0 ±  1.0 
TABLE  IX 
Effect of Cycloheximide on C3a-induced  MGP Release 
MGP release (percent 
Experimental condition  increase above 
control) 
C3a (10 ug/ml) 
Cycloheximide (10 #g/ml) 
C3a plus cycloheximide 
Methacholine (1 #M) 
Methacholine plus cycloheximide 
27 -+ 1.0 
4_+0.2 
30 +  3.0 
34 _+ 1.0 
33 _+ 2.5 
stimulating MMS synthesis.  In this experiment, cycloheximide-treated airways, 
and airways cultured in parallel in the absence of cycloheximide, were challenged 
with  C3a  or the muscarinic agonist,  methacholine (Table  IX).  Cycloheximide 
had no effect on spontaneous MGP release, and also failed to influence either 
C3a or methacholine-stimulated MGP release. Thus, it is unlikely that C3a acts 
to stimulate MGP release by activating MMS generation. 
Discussion 
The anaphylatoxin, C3a, generated during complement activation, can stim- 
ulate a variety of biologic responses by interacting with mast cells (20), basophils 
and eosinophils (24,  25),  neutrophils (26,  27), and macrophages (21,  28).  It is 
very likely that anaphylatoxins play a role in host defense mechanisms, particu- 
larly those causing inflammation. While there is no current documentation of 
anaphylatoxin generation during pulmonary infections in humans, it is likely that 
complement activation occurs, particularly during the course of infections asso- 
ciated  with  IgG  antibody  formation.  As  mucus  secretion accompanies  many 
pulmonary infections, it was appropriate to determine whether C3a influences 
MGP release. C3a was found to be a potent mucus secretagogue, with impressive 
activity at concentrations as low as 5 gg/ml--amounts generated by activation 
of <10% of normal serum complement. The activity of C3a was rapid, causing 
MGP release within 30 min, and specific, as reflected in the ability ofC3a antisera 
to prevent or absorb C3a activity. In addition, it was demonstrated that C3a des 
Arg did not produce such activity. 
Neither the role of mucus not" the mechanisms responsible for its secretion in MAROM  ET  AL.  665 
different pulmonary diseases is clear, although  recent studies have uncovered a 
number of putative secretagogues, including  neurohormones  (1-5),  mast cell- 
derived mediators (4, 6-9), and a molecule termed MMS, released from human 
pulmonary macrophages and peripheral blood monocytes after surface activation 
(22, 29). Thus, it became important to examine whether the secretion-stimulating 
activity of C3a is related to the generation  of any of these recognized secreta- 
gogues. 
C3a is capable of activating mast cells and releasing histamine from pulmonary 
tissue (30);  therefore,  in  several experiments  where C3a had  stimulated  MGP 
release, histamine  levels in the same supernatants  were measured.  No increase 
in  histamine  release was observed in  four separate experiments  in which C3a- 
treated  airways  were  compared  to  control  airways.  In  order  to  validate  this 
observation,  histamine  was incubated  with  airways,  and  its complete recovery 
after a  4-h incubation  was documented.  Thus,  this data indicated that C3a did 
not cause detectable histamine release in these cultured airways. This observation 
was explored further by comparing the activity of C3a with reversed anaphylaxis. 
Both C3a and reversed anaphylaxis led to increased MGP release, but the former 
was not associated with detectable histamine release, while the latter was. More- 
over,  cAMP  inhibited  both  the  MGP  and  the  histamine  release  induced  by 
reversed anaphylaxis,  while having  no  effect on  C3a actions.  Therefore,  C3a 
does not act as a mucus secretagogue through mast cell histamine release. 
Arachidonic acid, several prostaglandins, several hydroxyeicosatetraenoic acids 
(HETE) and hydroperoxy-eicosatetraenoic acids, and leukotrienes C4 and D4 are 
potent mucus secretagogues (6, 7, 9). C5a is capable of stimulating leukotriene 
D4 formation  from pulmonary tissue (31) and causing prostaglandin  formation 
from  neutrophiis  (32),  while  terminal  complement  components cleave arachi- 
donic acid from the cell membrane and cause prostaglandin,  thromboxane, and 
HETE formation (33). C3a stimulates macrophages to release thromboxane (34) 
and  causes neutrophils  to generate  leukotrienes  (32).  Thus,  it was essential to 
examine  the  relationship  between C3a-induced  MGP secretion and  eicosanoid 
formation. 
The  first approach  used  was to  modulate  cyclooxygenase and  lipoxygenase 
pathways of archidonic acid metabolism by pharmacologic inhibitors.  ETYA, in 
concentrations that inhibit both enzymes (6), did not influence C3a stimulation 
of MGP release.  In data not presented,  aspirin and indomethacin,  which selec- 
tively inhibit the cyclooxygenase pathway, also failed to affect C3a-induced MGP 
secretion. Thus, impairment  of both enzymatic pathways involved in the oxida- 
tion  of arachidonic  acid  failed  to  influence  C3a  actions  on  MGP  release.  In 
another  experiment,  diethylether  extracts  of airway  supernatants  after  C3a 
treatment  were  analyzed  by  HPLC,  and  no  leukotrienes  were  found.  This 
experiment was validated by demonstrating that LTC4 added to airway in culture 
was not metabolized significantly during a 4-h incubation. Thus, several lines of 
evidence indicate that  C3a does not cause MGP release from airways through 
the generation of eicosanoids. Therefore, we conclude that the effect of C3a on 
MGP release is not through histamine or eicosanoid release from airway tissue. 
Since pulmonary  macrophages constitute a  major cell  type found in  human 
airways, and the time course of C3a-induced MGP release approximates the peak 666  C3a  ENHANCES MUCOUS GLYCOPROTEIN RELEASE 
of MMS  release  from  macrophages  (22),  it  was  conceivable  that  C3a  acted 
through the generation of MMS. However, MMS is synthesized by macrophages 
through a cycloheximide-inhibitable pathway. Therefore, we used cycloheximide 
to determine whether C3a action paralleled MMS synthesis. Neither C3a nor the 
muscarinic agonist methacholine was influenced by prior exposure of the airways 
to cycloheximide.  Therefore,  it  is  unlikely  that  C3a acts by stimulating  MMS 
formation. 
In conclusion, C3a is a potent mucus secretagogue, but its mechanism of action 
is unclear. The data indicate that mast cells are probably not involved, although 
it is possible that mast cells in close proximity to mucous glands release mediators 
that stimulate glandular  activity without achieving detectable concentrations in 
the diffusate. It also appears that neither arachidonic acid products nor macro- 
phage generation of MMS is involved in these C3a actions. Therefore, it seems 
possible that C3a acts directly on mucous glands (and/or globet cells) to directly 
stimulate  MGP release.  Regardless  of the  mechanism,  the  capacity of C3a  to 
stimulate  mucus secretion is an additional,  potentially important  activity to be 
included in the spectrum of actions caused by this anaphylatoxin. 
Summary 
Because C3a may be generated during the course of pulmonary inflammatory 
reactions, we investigated the ability of C3a to affect mucous glycoprotein (MGP) 
secretion  from  cultured  human  airways.  C3a,  but not  C3a des Arg,  caused a 
dose-related increase in MGP release (maximal after 4-6 h), with as little as  15 
~g of C3a per milliliter stimulating a 40% increase. 
The experimental  evidence suggested that immunologically specific C3a was 
required  for the  secretagogue actions,  as  monospecific anti-C3a  inhibited  the 
reaction, as well as specifically absorbing the secretagogue from solution. More- 
over,  it  appeared  that  C3a  does  not  require  mast  cell  activation,  eicosanoid 
generation,  or macrophage-derived  mucus secretagogue synthesis for its effect, 
since  (a)  no  evidence  of histamine  release  accompanied  C3a-induced  MGP 
release,  and  dibutyryi cAMP failed  to affect C3a-induced  MGP release,  while 
reducing the actions of reversed anaphylaxis; (b) MGP release caused by C3a was 
not influenced by eicosatetraynoic acid or specific cyclooxygenase inhibitors, and 
no leukotrienes were detectable on the supernatants  of C3a-stimulated airways; 
and  (c) cycloheximide failed to affect C3a secretion-stimulating  actions.  Thus, 
C3a is a  potent  mucus secretagogue,  and,  possibly, acts directly as a  glandular 
stimulant.  It seems likely that C3a generated in the course of pulmonary inflam- 
mation  might  contribute  to  the  mucus  secretion  associated  with  pulmonary 
infections. 
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